메뉴 건너뛰기




Volumn 6, Issue 3, 2013, Pages 360-366

Journey through cholesteryl ester transfer protein inhibition : from bench to bedside

Author keywords

Atherosclerosis; High density lipoprotein; Lipids and lipoprotein metabolism

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TORCETRAPIB;

EID: 84884487596     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.111.000014     Document Type: Review
Times cited : (11)

References (67)
  • 2
    • 21844467979 scopus 로고    scopus 로고
    • New insights into the regulation of HDL metabolism and reverse cholesterol transport
    • Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232.
    • (2005) Circ Res. , vol.96 , pp. 1221-1232
    • Lewis, G.F.1    Rader, D.J.2
  • 4
    • 0024996141 scopus 로고
    • Plasma high density lipoproteins. Metabolism and relationship to atherogenesis
    • Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
    • (1990) J Clin Invest. , vol.86 , pp. 379-384
    • Tall, A.R.1
  • 6
    • 11144246298 scopus 로고    scopus 로고
    • Scavenger receptor class B type i is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice
    • Out R, Hoekstra M, Spijkers JA, Kruijt JK, van Eck M, Bos IS, Twisk J, Van Berkel TJ. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. J Lipid Res. 2004;45:2088-2095.
    • (2004) J Lipid Res. , vol.45 , pp. 2088-2095
    • Out, R.1    Hoekstra, M.2    Spijkers, J.A.3    Kruijt, J.K.4    Van Eck, M.5    Bos, I.S.6    Twisk, J.7    Van Berkel, T.J.8
  • 7
    • 33646678433 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein inhibition: Effect on reverse cholesterol transport?
    • Rensen PC, Havekes LM. Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006;26:681-684.
    • (2006) Arterioscler Thromb Vasc Biol. , vol.26 , pp. 681-684
    • Rensen, P.C.1    Havekes, L.M.2
  • 9
    • 37049244034 scopus 로고
    • The role of lipids and lipoproteins in atherosclerosis
    • Gofman JW, Lindgren F. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111:166-171.
    • (1950) Science. , vol.111 , pp. 166-171
    • Gofman, J.W.1    Lindgren, F.2
  • 10
    • 0016433018 scopus 로고
    • Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease
    • Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-19.
    • (1975) Lancet. , vol.1 , pp. 16-19
    • Miller, G.J.1    Miller, N.E.2
  • 11
    • 0017280786 scopus 로고
    • Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men
    • Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med. 1976;294:293-298.
    • (1976) N Engl J Med. , vol.294 , pp. 293-298
    • Rhoads, G.G.1    Gulbrandsen, C.L.2    Kagan, A.3
  • 12
    • 0017384270 scopus 로고
    • High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study
    • Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
    • (1977) Am J Med. , vol.62 , pp. 707-714
    • Gordon, T.1    Castelli, W.P.2    Hjortland, M.C.3    Kannel, W.B.4    Dawber, T.R.5
  • 13
    • 0017614773 scopus 로고
    • The Tromsø heart-study: High-density lipoprotein and coronary heart-disease: A prospective casecontrol study
    • Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study: high-density lipoprotein and coronary heart-disease: a prospective casecontrol study. Lancet. 1977;1:965-968.
    • (1977) Lancet. , vol.1 , pp. 965-968
    • Miller, N.E.1    Thelle, D.S.2    Forde, O.H.3    Mjos, O.D.4
  • 14
    • 0034496618 scopus 로고    scopus 로고
    • HDLcholesterol as a marker of coronary heart disease risk: The Québec cardiovascular study
    • Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDLcholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis. 2000;153:263-272.
    • (2000) Atherosclerosis. , vol.153 , pp. 263-272
    • Després, J.P.1    Lemieux, I.2    Dagenais, G.R.3    Cantin, B.4    Lamarche, B.5
  • 17
    • 0023232216 scopus 로고
    • Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
    • (1987) N Engl J Med. , vol.317 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3    Heinonen, O.P.4    Heinsalmi, P.5    Helo, P.6    Huttunen, J.K.7    Kaitaniemi, P.8    Koskinen, P.9    Manninen, V.10
  • 18
    • 0026754428 scopus 로고
    • Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Münster study
    • Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Münster study. Am J Cardiol. 1992;70:733-737.
    • (1992) Am J Cardiol. , vol.70 , pp. 733-737
    • Assmann, G.1    Schulte, H.2
  • 19
    • 34447511196 scopus 로고    scopus 로고
    • Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
    • Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
    • (2007) JAMA. , vol.298 , pp. 299-308
    • Nordestgaard, B.G.1    Benn, M.2    Schnohr, P.3    Tybjaerg-Hansen, A.4
  • 20
    • 0034739457 scopus 로고    scopus 로고
    • Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study
    • Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City Heart Study. Circulation. 2000;102:2197-2203.
    • (2000) Circulation. , vol.102 , pp. 2197-2203
    • Agerholm-Larsen, B.1    Tybjaerg-Hansen, A.2    Schnohr, P.3    Steffensen, R.4    Nordestgaard, B.G.5
  • 21
    • 0034712706 scopus 로고    scopus 로고
    • Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene
    • Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation. 2000;101:1907-1912.
    • (2000) Circulation. , vol.101 , pp. 1907-1912
    • Agerholm-Larsen, B.1    Nordestgaard, B.G.2    Steffensen, R.3    Jensen, G.4    Tybjaerg-Hansen, A.5
  • 23
    • 0038798088 scopus 로고    scopus 로고
    • Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: The Copenhagen City Heart Study
    • Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol. 2003;41:1972-1982.
    • (2003) J Am Coll Cardiol. , vol.41 , pp. 1972-1982
    • Andersen, R.V.1    Wittrup, H.H.2    Tybjaerg-Hansen, A.3    Steffensen, R.4    Schnohr, P.5    Nordestgaard, B.G.6
  • 25
    • 84892679085 scopus 로고    scopus 로고
    • Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)
    • Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA.
    • JAMA
  • 26
    • 0032917975 scopus 로고    scopus 로고
    • Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression
    • Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999;19:1105-1110.
    • (1999) Arterioscler Thromb Vasc Biol. , vol.19 , pp. 1105-1110
    • Plump, A.S.1    Masucci-Magoulas, L.2    Bruce, C.3    Bisgaier, C.L.4    Breslow, J.L.5    Tall, A.R.6
  • 28
    • 68949207221 scopus 로고    scopus 로고
    • Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice
    • de Vries-van der Weij J, Zadelaar S, Toet K, Havekes LM, Kooistra T, Rensen PC. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis. 2009;206:153-158.
    • (2009) Atherosclerosis. , vol.206 , pp. 153-158
    • De Vries-Van Der Weij, J.1    Zadelaar, S.2    Toet, K.3    Havekes, L.M.4    Kooistra, T.5    Rensen, P.C.6
  • 30
    • 0032570684 scopus 로고    scopus 로고
    • Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
    • Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033-5036.
    • (1998) J Biol Chem. , vol.273 , pp. 5033-5036
    • Sugano, M.1    Makino, N.2    Sawada, S.3    Otsuka, S.4    Watanabe, M.5    Okamoto, H.6    Kamada, M.7    Mizushima, A.8
  • 31
    • 74549148035 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    • Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164.
    • (2010) Eur Heart J. , vol.31 , pp. 149-164
    • Chapman, M.J.1    Le Goff, W.2    Guerin, M.3    Kontush, A.4
  • 36
    • 16944362351 scopus 로고    scopus 로고
    • Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity
    • Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997;17:1053-1059.
    • (1997) Arterioscler Thromb Vasc Biol. , vol.17 , pp. 1053-1059
    • Hirano, K.1    Yamashita, S.2    Nakajima, N.3    Arai, T.4    Maruyama, T.5    Yoshida, Y.6    Ishigami, M.7    Sakai, N.8    Kameda-Takemura, K.9    Matsuzawa, Y.10
  • 38
    • 67649367650 scopus 로고    scopus 로고
    • Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study
    • Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2:26-33.
    • (2009) Circ Cardiovasc Genet. , vol.2 , pp. 26-33
    • Ridker, P.M.1    Paré, G.2    Parker, A.N.3    Zee, R.Y.4    Miletich, J.P.5    Chasman, D.I.6
  • 41
    • 73349122606 scopus 로고    scopus 로고
    • Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community
    • Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB, Ordovas JM. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation. 2009;120:2414-2420.
    • (2009) Circulation. , vol.120 , pp. 2414-2420
    • Vasan, R.S.1    Pencina, M.J.2    Robins, S.J.3    Zachariah, J.P.4    Kaur, G.5    D'Agostino, R.B.6    Ordovas, J.M.7
  • 42
    • 33644775588 scopus 로고    scopus 로고
    • Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
    • Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537-552.
    • (2006) J Lipid Res. , vol.47 , pp. 537-552
    • Clark, R.W.1    Ruggeri, R.B.2    Cunningham, D.3    Bamberger, M.J.4
  • 50
    • 71749117559 scopus 로고    scopus 로고
    • Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    • Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol. 2009;104(suppl 10):10E-15E.
    • (2009) Am J Cardiol. , vol.104 , Issue.SUPPL. 10
    • Barter, P.1
  • 52
    • 58149386896 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
    • Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506-2514.
    • (2008) Circulation. , vol.118 , pp. 2506-2514
    • Nicholls, S.J.1    Tuzcu, E.M.2    Brennan, D.M.3    Tardif, J.C.4    Nissen, S.E.5
  • 53
    • 0034644214 scopus 로고    scopus 로고
    • A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
    • Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
    • (2000) Nature. , vol.406 , pp. 203-207
    • Okamoto, H.1    Yonemori, F.2    Wakitani, K.3    Minowa, T.4    Maeda, K.5    Shinkai, H.6
  • 55
    • 17444372760 scopus 로고    scopus 로고
    • Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia
    • Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, Trip MD, Kastelein JJ. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95:1085-1088.
    • (2005) Am J Cardiol. , vol.95 , pp. 1085-1088
    • Kuivenhoven, J.A.1    De Grooth, G.J.2    Kawamura, H.3    Klerkx, A.H.4    Wilhelm, F.5    Trip, M.D.6    Kastelein, J.J.7
  • 56
    • 84863789387 scopus 로고    scopus 로고
    • Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
    • Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 2012;53:1755-1766.
    • (2012) J Lipid Res. , vol.53 , pp. 1755-1766
    • Barter, P.J.1    Rye, K.A.2
  • 60
    • 84859517252 scopus 로고    scopus 로고
    • Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial
    • dal-VESSEL Investigators
    • Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, Kastelein JJ, Deanfield JE; dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857-865.
    • (2012) Eur Heart J. , vol.33 , pp. 857-865
    • Lüscher, T.F.1    Taddei, S.2    Kaski, J.C.3    Jukema, J.W.4    Kallend, D.5    Münzel, T.6    Kastelein, J.J.7    Deanfield, J.E.8
  • 65
    • 81255125373 scopus 로고    scopus 로고
    • Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial
    • Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099-2109.
    • (2011) JAMA. , vol.306 , pp. 2099-2109
    • Nicholls, S.J.1    Brewer, H.B.2    Kastelein, J.J.3    Krueger, K.A.4    Wang, M.D.5    Shao, M.6    Hu, B.7    McErlean, E.8    Nissen, S.E.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.